Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDAL trial of radium-223 in oligometastatic castration-resistant prostate cancer
jRCTs031200358Active, not recruiting
- Sponsor
- Bayer
- Start
- Mar 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Randomised, open-label trial of radium-223 dichloride in prostate cancer (PCa) (2 arms), sponsored by Bayer. Primary endpoint: Progression-free survival to progression of bone metastases on whole body diffusion-weighted MRI. Started Mar 2021; status: active, not recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs031200358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200358.